Skip to main content
Pharnext logo

Pharnext — Investor Relations & Filings

Ticker · ALPHA ISIN · FR0011191287 LEI · 969500KJGF9ZUYXSMJ27 Euronext Growth Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2021-07-15 Board/Management Inform…
Country FR France
Listing Euronext Growth ALPHA

About Pharnext

https://pharnext.com/

Pharnext is an advanced clinical-stage biopharmaceutical company that develops novel therapeutics for neurodegenerative diseases lacking curative or satisfactory treatments. The company's approach is based on its proprietary Pleotherapy™ platform, which uses network pharmacology to identify and develop synergistic combinations of already-approved drugs at new, lower doses. This strategy aims to create more effective and safer treatments. Pharnext's lead product candidate, PXT3003, is an oral fixed-dose combination therapy in development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating inherited peripheral neuropathy.

Recent filings

Filing Released Lang Actions
Piers Morgan Joins Pharnext's Board of Directors
Board/Management Information Classification · 1% confidence The document explicitly announces the appointment of Piers Morgan to Pharnext's Board of Directors and notes that he will chair the Audit Committee. This content directly relates to changes in the company's board and senior governance structure. This aligns perfectly with the definition for Board/Management Information (MANG). It is not an earnings release (ER), a full annual report (10-K), or a proxy statement (PSI).
2021-07-15 English
Piers Morgan rejoint le Conseil d'Administration de Pharnext
Board/Management Information Classification · 1% confidence The document is a press release announcing a specific corporate event: the appointment of Piers Morgan to the Board of Directors and as Chairman of the Audit Committee. This type of announcement, detailing changes in senior management or the board, directly corresponds to the definition of 'Board/Management Information' (MANG). It is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI). The content focuses entirely on personnel changes at the management/board level.
2021-07-15 French
Pharnext Announces First Patient Enrolled in Europe in the PREMIER Trial, its Pivotal Phase III Clinical Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A ('CMT1A')
Regulatory Filings Classification · 1% confidence The document is a press release dated July 12, 2021, announcing a specific operational milestone: the enrollment of the first patient in Europe for the pivotal Phase III clinical study (PREMIER trial) of PXT3003 for CMT1A. It details the trial objectives, expected timelines for results (3Q 2023), and regulatory submissions (1H 2024). This type of announcement, focusing on clinical trial progress and key operational updates rather than comprehensive financial results (like a 10-K or IR) or a formal transcript (CT), is best classified as a general corporate announcement. Since it is not a specific filing like a Director's Dealing (DIRS), Dividend Notice (DIV), or Capital Change (CAP), and it is not merely announcing the publication of a report (RPA), it falls under the general category for corporate news releases that don't fit elsewhere, which is Regulatory Filings (RNS) in this context, as it is a material update released to the public/market.
2021-07-12 English
Pharnext annonce l'inclusion du premier patient en Europe dans l'essai PREMIER, son étude clinique pivot de Phase III de PXT3003 dans la maladie de Charcot-Marie-Tooth de type 1A (CMT1A)
Regulatory Filings Classification · 1% confidence The document is a press release dated July 12, 2021, announcing a significant operational milestone: the inclusion of the first European patient in the Phase III clinical trial (PREMIER) for their drug PXT3003 for CMT1A. It details the trial status, expected timelines for results and regulatory submission, and provides background on the disease, the drug, and the company. This type of announcement, focusing on clinical trial progress and operational updates rather than comprehensive financial results (like 10-K or IR) or formal regulatory filings, is best classified as an Earnings Release (ER) if it were tied to a reporting period, or more generally, a Regulatory Filing (RNS) if it doesn't fit other specific categories. However, given the content is a specific, time-sensitive operational update about a clinical trial milestone, it strongly resembles an Earnings Release (ER) which often includes operational highlights, or potentially an Investor Presentation (IP) if it were a slide deck, but as a text release, ER is the closest fit for a major operational update, although RNS is a strong secondary candidate if ER is strictly reserved for financial results. Since it is a major announcement about clinical progress, which often accompanies or substitutes for quarterly updates, and it is not a formal financial report, I will classify it as an Earnings Release (ER) as it communicates key performance/progress indicators, or RNS as a general announcement. Given the context of a clinical trial update, which is a key operational metric for a biotech, ER is often used for such announcements when they are not strictly financial results. However, since it is not explicitly stating 'Earnings' or 'Financial Results', RNS (Regulatory Filings/General Announcement) is the safest fit for a non-financial, non-presentation, non-management change announcement. Let's re-evaluate against the definitions. It is not a 10-K, AR, CT, DIV, DEF 14A, etc. It is a specific announcement of progress. It is not a Report Publication Announcement (RPA) because it *is* the information, not just an announcement *that* a report is attached. It is a general corporate announcement. Therefore, RNS (Regulatory Filings / fallback) is the most appropriate category for this type of press release detailing clinical trial progress.
2021-07-12 French
Pharnext: Shareholder Letter
Legal Proceedings Report Classification · 1% confidence The document is explicitly titled and structured as a "Shareholder Letter" from the CEO, dated June 17, 2021. This format is typically used to communicate key updates, strategic direction, and financial context directly to investors, often accompanying or summarizing other filings. While it discusses financing (CAP) and clinical trial progress (IR/ER context), the primary delivery mechanism and content structure align best with a direct communication to shareholders, which often falls under Investor Relations material. Given the options, 'Investor Presentation' (IP) is for detailed slide decks, 'Earnings Release' (ER) is for formal results, and 'Interim Report' (IR) is for comprehensive financials. A CEO letter summarizing progress, financing, and outlook, especially when not explicitly labeled as a formal quarterly report, is best classified as a general investor communication. However, since it contains substantial operational and financial updates (financing details, trial progress, market outlook), it is more substantive than a simple 'Report Publication Announcement' (RPA). In many databases, a formal CEO letter detailing strategy and progress is often grouped with Investor Presentations or sometimes treated as a specific type of Investor Relations document. Since 'Investor Presentation' (IP) is the closest fit for a detailed, non-standardized investor communication that isn't a formal financial report (10-K, IR, ER), I will select IP, as it conveys detailed strategic information directly to investors, similar to a presentation narrative. The document is too long and detailed to be an RPA or RNS fallback.
2021-06-21 English
Pharnext: Lettre aux Actionnaires
Investor Presentation Classification · 1% confidence The document is titled "Lettre aux Actionnaires" (Letter to Shareholders) and is dated June 17, 2021. It contains a detailed update from the CEO regarding clinical trial progress (PXT3003 Phase III PREMIER trial), financing activities (convertible bond financing), and future outlook. This format—a direct communication from management to shareholders providing operational and financial updates outside of a formal quarterly or annual report—is characteristic of an Investor Presentation or a detailed shareholder letter. Since it is a comprehensive update covering strategy, financing, and clinical pipeline status, it aligns best with the 'Investor Presentation' (IP) category, which covers detailed presentations focusing on financials, strategy, and market position. It is not a short announcement (RPA/RNS), nor is it a formal regulatory filing like a 10-K or an Earnings Release (ER).
2021-06-21 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.